MAPT and Alzheimer disease: One possible explanation for these findings is that, in the clinical stages of AD, pathological changes of CSF Aβ1–42 may have reached the maximum level and remain relatively stable, while changes in tau and ptau-181 concentrations are still ongoing and more closely associated with cognitive performance [8].